BioClin Therapeutics' Series B - II Round

BioClin Therapeutics raised a round of funding on May 09, 2018.

BioClin Therapeutics is a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet…

Articles about BioClin Therapeutics' Series B - II Round: